Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dermatitis, Chronic Clear all
Completed Phase 1 Interventional

Treatment of Chronic Itch in Atopic Dermatitis (Eczema): Nerve Function

NCT02268448
View directory record Official record
Conditions
Cutaneous Nerves CNS Itch
Interventions
Clonidine, Naltrexone
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 22, 2026, 1:56 AM EDT
Active, not recruiting No phase listed Observational

A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

NCT03661866
View directory record Official record
Conditions
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2050
U.S. locations
54
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis

NCT01806662
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ustekinumab, Placebo
Drug · Other
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases

NCT03858634
View directory record Official record
Conditions
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus, Plaque Psoriasis
Interventions
KPL-716, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
14
States / cities
Anniston, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 22, 2026, 1:56 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • North Little Rock, Arkansas + 32 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

NCT00817063
View directory record Official record
Conditions
Eczema
Interventions
alitretinoin, Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
70
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 64 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

NCT01544595
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Jul 22, 2026, 1:56 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis

NCT00691366
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis

NCT01358578
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Placebo, secukinumab (AIN457), etanercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 4 Interventional

Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis

NCT00667056
View directory record Official record
Conditions
Dermatitis
Interventions
tacrolimus ointment, placebo ointment
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
17 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Kansas City, Kansas • Shawnee, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Jul 22, 2026, 1:56 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus

NCT06787586
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Chronic Pruritus
Interventions
ATTO-1310, ATTO-1310 Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
11
States / cities
Encinitas, California • Rocklin, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 4 Interventional Results available

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

NCT01323673
View directory record Official record
Conditions
Dermatitis, Chronic
Interventions
clobetasol propionate 0.05%, Vehicle / Placebo
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
10
States / cities
San Diego, California • Boynton Beach, Florida • West Palm Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream

NCT02411162
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Combination therapy GSK2894512 Cream A + GSK2894512 Cream B, Combination therapy Vehicle Cream A + Vehicle Cream B
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT04018027
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, difelikefalin 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Jul 22, 2026, 1:56 AM EDT
Terminated Not applicable Interventional

A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema

NCT01826630
View directory record Official record
Conditions
Eczema, Hand Eczema, Atopic Dermatitis
Interventions
CLn BodyWash, Cetaphil Daily Facial Cleanser
Other
Lead sponsor
Shari L Hand
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Gahanna, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand Dermatitis

NCT00828464
View directory record Official record
Conditions
Hand Dermatosis
Interventions
clobetasol propionate
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Jul 22, 2026, 1:56 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

NCT01910818
View directory record Official record
Conditions
Chronic Radiation Dermatitis
Interventions
Fractional CO2 laser treatment, No treatment
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Jul 22, 2026, 1:56 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06840392
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1, Placebo 2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Withdrawn Phase 3 Interventional

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

NCT05219864
View directory record Official record
Conditions
Hand Eczema
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Encino, California • Fountain Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Jul 22, 2026, 1:56 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 22, 2026, 1:56 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

NCT04140695
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Hoover, Alabama • Tempe, Arizona • Encino, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Jul 22, 2026, 1:56 AM EDT
Active, not recruiting Phase 2 Interventional

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

NCT06993610
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Tibulizumab Dose A, Tibulizumab Dose B, Placebo
Biological · Other
Lead sponsor
Zura Bio Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 22, 2026, 1:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

NCT02743871
View directory record Official record
Conditions
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions
PF-06817024, Placebo for PF-06817024
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Jul 22, 2026, 1:56 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

NCT04154033
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Dermatitis
Interventions
Naltrexone, Placebo Cream
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Jul 22, 2026, 1:56 AM EDT